|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||21.65 - 22.56|
|52 Week Range||14.23 - 25.13|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||20.50|
|Forward Dividend & Yield||0.62 (2.94%)|
|Ex-Dividend Date||Sep 28, 2020|
|1y Target Est||N/A|
Asahi Kasei renewed its membership in the Business Call to Action (BCtA) led by the United Nations Development Programme (UNDP) in February 2021 with businesses in India for Bemberg™ regenerated cellulose fiber (cupro) and Microza™ polyvinylidene fluoride (PVDF) hollow-fiber membrane.
Asahi Kasei Medical announces that an affiliated company in China, Asahi Kasei Bioprocess (Shanghai) Co., Ltd. (AKBC), started business on April 1, 2021.
Rating Action: Moody's affirms AGC at A2; changes outlook to negativeGlobal Credit Research - 29 Mar 2021Tokyo, March 29, 2021 -- Moody's Japan K.K. has affirmed AGC Inc.'s A2 issuer rating.At the same time, Moody's has revised AGC's outlook to negative from stable.Moody's has also affirmed the Prime-1 backed commercial paper rating of its subsidiary AGC Capital, Inc."The negative outlook reflects our view that AGC's legacy glass business will continue to be a drag on profits and underpins its competitive position, which is more comparable to lower rated global peers," says Ryohei Nishio, a Moody's Analyst.RATINGS RATIONALEThe negative outlook reflects the difficulties AGC faces in restructuring its legacy glass segment, which constitutes about half of its consolidated sales. Profitability of its glass segment had peaked in the year ending 31 December 2016 and structurally declined thereafter with margins in the low single digits.